These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22433712)

  • 1. Development of a novel approach, the epigenome-based outlier approach, to identify tumor-suppressor genes silenced by aberrant DNA methylation.
    Kikuyama M; Takeshima H; Kinoshita T; Okochi-Takada E; Wakabayashi M; Akashi-Tanaka S; Ogawa T; Seto Y; Ushijima T
    Cancer Lett; 2012 Sep; 322(2):204-12. PubMed ID: 22433712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers.
    Conway KE; McConnell BB; Bowring CE; Donald CD; Warren ST; Vertino PM
    Cancer Res; 2000 Nov; 60(22):6236-42. PubMed ID: 11103776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines.
    Imura M; Yamashita S; Cai LY; Furuta J; Wakabayashi M; Yasugi T; Ushijima T
    Cancer Lett; 2006 Sep; 241(2):213-20. PubMed ID: 16303245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer.
    Yan PS; Shi H; Rahmatpanah F; Hsiau TH; Hsiau AH; Leu YW; Liu JC; Huang TH
    Cancer Res; 2003 Oct; 63(19):6178-86. PubMed ID: 14559801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer.
    Alvarez C; Tapia T; Cornejo V; Fernandez W; Muñoz A; Camus M; Alvarez M; Devoto L; Carvallo P
    Mol Carcinog; 2013 Jun; 52(6):475-87. PubMed ID: 22315090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and promoter methylation of the RASSF1A gene in sporadic breast cancers in Chinese women.
    Li Y; Wei Q; Cao F; Cao X
    Oncol Rep; 2008 May; 19(5):1149-53. PubMed ID: 18425370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of PRTFDC1 silencing and aberrant promoter methylation of GPR150, ITGA8 and HOXD11 in ovarian cancers.
    Cai LY; Abe M; Izumi S; Imura M; Yasugi T; Ushijima T
    Life Sci; 2007 Mar; 80(16):1458-65. PubMed ID: 17303177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of 27 5' CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers.
    Hagihara A; Miyamoto K; Furuta J; Hiraoka N; Wakazono K; Seki S; Fukushima S; Tsao MS; Sugimura T; Ushijima T
    Oncogene; 2004 Nov; 23(53):8705-10. PubMed ID: 15467763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
    Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
    Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
    Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
    Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation.
    Seng TJ; Low JS; Li H; Cui Y; Goh HK; Wong ML; Srivastava G; Sidransky D; Califano J; Steenbergen RD; Rha SY; Tan J; Hsieh WS; Ambinder RF; Lin X; Chan AT; Tao Q
    Oncogene; 2007 Feb; 26(6):934-44. PubMed ID: 16862168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
    Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
    Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia.
    Gebhard C; Schwarzfischer L; Pham TH; Schilling E; Klug M; Andreesen R; Rehli M
    Cancer Res; 2006 Jun; 66(12):6118-28. PubMed ID: 16778185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer.
    Chen H; Suzuki M; Nakamura Y; Ohira M; Ando S; Iida T; Nakajima T; Nakagawara A; Kimura H
    Oncol Rep; 2006 May; 15(5):1281-5. PubMed ID: 16596198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of promoter hypermethylation of RASSF1A, RARbeta2, BRCA1 and HOXA5 in breast cancers of Indian patients.
    Bagadi SA; Prasad CP; Kaur J; Srivastava A; Prashad R; Gupta SD; Ralhan R
    Life Sci; 2008 Jun; 82(25-26):1288-92. PubMed ID: 18538349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
    Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
    Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent epigenetic inactivation of the SLIT2 gene in gliomas.
    Dallol A; Krex D; Hesson L; Eng C; Maher ER; Latif F
    Oncogene; 2003 Jul; 22(29):4611-6. PubMed ID: 12881718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
    Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
    Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer.
    Lee S; Oh T; Chung H; Rha S; Kim C; Moon Y; Hoehn BD; Jeong D; Lee S; Kim N; Park C; Yoo M; An S
    Int J Oncol; 2012 Mar; 40(3):889-98. PubMed ID: 22038115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
    Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
    Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.